FI20085733A - Methods for treating disease using Sertoli cells and allografts or xenografts - Google Patents

Methods for treating disease using Sertoli cells and allografts or xenografts Download PDF

Info

Publication number
FI20085733A
FI20085733A FI20085733A FI20085733A FI20085733A FI 20085733 A FI20085733 A FI 20085733A FI 20085733 A FI20085733 A FI 20085733A FI 20085733 A FI20085733 A FI 20085733A FI 20085733 A FI20085733 A FI 20085733A
Authority
FI
Finland
Prior art keywords
cells
sertoli cells
allografts
xenografts
methods
Prior art date
Application number
FI20085733A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI120696B (en
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of FI20085733A publication Critical patent/FI20085733A/en
Application granted granted Critical
Publication of FI120696B publication Critical patent/FI120696B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention describes a method of treating a disease that results from a deficiency of a biological factor which includes administering to a mammal Sertoli cells and cells that produce the biological factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site in a mammal for cellular transplants is further described by the present invention. A pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is also provided.
FI20085733A 1994-04-13 2008-07-18 A method for increasing cellular recovery and proliferation FI120696B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
US21169594 1994-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts
US9504565 1995-04-13

Publications (2)

Publication Number Publication Date
FI20085733A true FI20085733A (en) 2008-07-18
FI120696B FI120696B (en) 2010-01-29

Family

ID=22787974

Family Applications (2)

Application Number Title Priority Date Filing Date
FI964033A FI120670B (en) 1994-04-13 1996-10-08 A pharmaceutical composition comprising Sertoli cells and their use
FI20085733A FI120696B (en) 1994-04-13 2008-07-18 A method for increasing cellular recovery and proliferation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI964033A FI120670B (en) 1994-04-13 1996-10-08 A pharmaceutical composition comprising Sertoli cells and their use

Country Status (12)

Country Link
US (3) US5725854A (en)
EP (1) EP0755258B1 (en)
JP (1) JPH09512015A (en)
AT (1) ATE212230T1 (en)
AU (1) AU715177B2 (en)
CA (1) CA2187803C (en)
DE (1) DE69525151T2 (en)
DK (1) DK0755258T3 (en)
ES (1) ES2169128T3 (en)
FI (2) FI120670B (en)
NO (1) NO320713B1 (en)
WO (1) WO1995028167A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293718B6 (en) * 1995-02-08 2004-07-14 Yamanouchi Europe B. V. Process for preparing a granulate containing orally active beta-lactam antibiotic and oral dosage-form containing the orally active beta-lactam antibiotic
US5830460A (en) * 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
WO1996028174A1 (en) * 1995-03-13 1996-09-19 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
NZ505459A (en) * 1998-01-02 2003-07-25 Titan Pharmaceuticals Inc Use of pigmented retinal epithelial cells for creation of an immune privilege site
ES2338076T3 (en) * 1998-11-06 2010-05-03 Sertoli Technologies, Inc. PRODUCTION OF A BIOLOGICAL FACTOR AND CREATION OF AN IMMUNOLOGICALLY PRIVILEGED ENVIRONMENT USING GENETICALLY ALTERED SERTOLI CELLS.
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
RO120313B1 (en) * 1998-12-15 2005-12-30 Universidad Nacional Autonoma De Mexico Device for favouring biological material implant
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
ES2272482T3 (en) 2000-01-20 2007-05-01 Diabcell Pty Limited PREPARATION AND XENOTRANSPLANT OF SWINE ISLOTS.
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
CA2421036A1 (en) 2000-09-20 2002-03-28 Islet Sheet Medical Llc Fabrication of thin sheet bio-artificial organs
WO2002092054A2 (en) * 2001-05-11 2002-11-21 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
EP1438395B1 (en) * 2001-09-28 2011-11-30 Diabcell Pty Limited Growing xenotransplant material in culture
US20050255111A1 (en) * 2002-02-22 2005-11-17 Olle Korsgren Use of an inhibitor or antagonist against tissue factor
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
CN1791670A (en) * 2003-06-24 2006-06-21 戴伯塞尔有限公司 Porcine pancreatic islet cultured with porcine sertoli cells for xenotransplantation
JP4926703B2 (en) * 2003-07-03 2012-05-09 セルトリ・テクノロジーズ・エルエルシー Compositions containing Sertoli cells and muscle-like cells and use of the compositions in cellular transplantation
WO2006118564A2 (en) * 2004-04-29 2006-11-09 Washington State University Research Foundation MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF
RU2401084C2 (en) 2004-07-29 2010-10-10 Юниверсити Оф Майами Hybrid cell-based therapy unit
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US20090028833A1 (en) * 2006-01-26 2009-01-29 John Constance M Proliferative Primary Human Sertoli Cell Cultures And Their Applications
EP2046351A2 (en) * 2006-07-28 2009-04-15 Sertocell Biotechnology (US) Corp. Adult sertoli cells and uses thereof
WO2009105278A2 (en) 2008-02-21 2009-08-27 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
DK3290061T3 (en) 2009-08-28 2020-07-13 Sernova Corp METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION
MX2010013135A (en) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Improved device and process for facilitating the transplant of biological material.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
WO2019079384A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System Delivery devices
US20220211770A1 (en) 2019-05-01 2022-07-07 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (en) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans Islands in pure form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
FI120696B (en) 2010-01-29
WO1995028167A1 (en) 1995-10-26
NO964342D0 (en) 1996-10-11
DE69525151D1 (en) 2002-03-14
CA2187803A1 (en) 1995-10-26
JPH09512015A (en) 1997-12-02
AU2289395A (en) 1995-11-10
CA2187803C (en) 1999-09-28
ES2169128T3 (en) 2002-07-01
NO320713B1 (en) 2006-01-23
US5759534A (en) 1998-06-02
US5843430A (en) 1998-12-01
ATE212230T1 (en) 2002-02-15
FI964033A (en) 1996-12-12
EP0755258B1 (en) 2002-01-23
AU715177B2 (en) 2000-01-20
DK0755258T3 (en) 2002-05-13
US5725854A (en) 1998-03-10
DE69525151T2 (en) 2002-08-14
NO964342L (en) 1996-12-13
FI120670B (en) 2010-01-29
EP0755258A1 (en) 1997-01-29
FI964033A0 (en) 1996-10-08

Similar Documents

Publication Publication Date Title
FI20085733A (en) Methods for treating disease using Sertoli cells and allografts or xenografts
SE8102193L (en) THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND ITS USE
DK0801649T3 (en) Hydroxylamine Derivatives Useful for Increasing Molecular Chaperone Production and Preparation thereof
MX9603074A (en) Vitamin e and derivatives prevent damage in red cells sterilized by phthalocyanines and light.
DK96588D0 (en) ANTITUMIR AGENT CONTAINING MACROMOLECULAR PLATINO COMPOUNDS
ATE151764T1 (en) NEW BENZOPYRAN DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AND PREPARATIONS CONTAINING THE COMPOUNDS
BR9710689A (en) Process for treating acute diarrhea and for providing therapy to a mammal having diarrhea and therapeutic preparation for reducing diarrhea symptoms
DK0702563T3 (en) Compositions and Methods for Treating Cancer and Hyperproliferative Diseases
DK0698109T3 (en) Gene transfer to pancreatic epithelial cells
CA2346644A1 (en) Method for preventing xenograft transplant rejection using photodynamic therapy
DK0804479T3 (en) Method of treating diabetes mellitus using KGF
DK0643775T3 (en) Quinone derivatives for enhancing cell bioenergy
BR9305783A (en) Process for preparing water-dispersible granules and water-dispersible granules
DK0900198T3 (en) Novel derivatives of vitamin D with carbo- or heterocyclic substituents on C-25, process for their preparation, intermediates and the use for the manufacture of drugs.
EA200100195A1 (en) INHIBITION OF THE TRANSPLANT AGAINST THE OWNER REACTION
NO951240D0 (en) Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus
DE3675197D1 (en) PYRIDINYLPYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THESE PLANT DISEASES PROTECTIVE CONTAINING THE ACTIVE SUBSTANCE.
DK1237562T3 (en) Process for the preparation of micania extracts containing micanolide and dihydromycanolide and use in the treatment of proliferative diseases
DE3881714D1 (en) ALKYL-SUBSTITUTED N-BENZOPYRANYLLACTAME, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS.
DK1189627T3 (en) Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin
JPS5398954A (en) L-ascorbic acid derivatives
EP0148025A3 (en) Antibodies and antibody-containing compositions for inhibiting periodontitis
DK0883406T3 (en) Use of IL-7 for the treatment of autoimmune diseases and especially insulin-dependent diabetes mellitus in particular
ATE106732T1 (en) MEDICATION PREPARATION CONTAINING STIGMASTA-4-EN-3-ONE AND USE THEREOF.
NO20012214D0 (en) Preparation of a Biological Factor and Creation of an Immunologically Beneficial Environment Using Genetically Modified Sertoli Cells

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120696

Country of ref document: FI

MA Patent expired